SCHEMBL1262033

SCHEMBL1262033

CC=C(c1cccc(F)c1OC)C(CC)[C@@](O)(C(=O)O)C(F)(F)F

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
CTSS P25774 4/20 0.40
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
CYP2D6 P10635 1/20 0.34
TSHR P16473 1/20 0.34
KRAS P01116 2/20 0.31
KDM4E B2RXH2 1/20 0.31
LMNA P02545 1/20 0.31
CTSK P43235 1/20 0.31
HCRTR1 O43613 1/20 0.30
HCRTR2 O43614 1/20 0.30
CYP3A4 P08684 1/20 0.30
GAA P10253 1/20 0.30
MAPT P10636 1/20 0.30
ALOX12 P18054 1/20 0.30
KMT2A Q03164 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1262057 0.87 CTSS (0.34) CTSSCYP2C9CYP2C19CYP2D6TSHR
SCHEMBL1261620 0.86 CTSS (0.33) CTSSCYP2C9CYP2C19CYP2D6TSHR
SCHEMBL1261144 0.85 CTSS (0.33) CTSSCYP2C9CYP2C19CYP2D6TSHR
SCHEMBL1262387 0.85 CTSS (0.33) CTSSCYP2C9CYP2C19CYP2D6TSHR
SCHEMBL4358219 0.75 HIF1A (0.36) CYP2C9CYP2D6MAPT
SCHEMBL3755099 0.72 CTSS (0.36) CTSSCYP2C9CYP2C19KRASKDM4E
SCHEMBL3755089 0.72 CTSS (0.36) CTSSCYP2C9CYP2C19KRASKDM4E
SCHEMBL3755093 0.72 CTSS (0.36) CTSSCYP2C9CYP2C19KRASKDM4E
SCHEMBL3531389 0.70 CTSS (0.33) CTSS
SCHEMBL3535623 0.70 CTSS (0.36) CTSSCYP2C9CYP2C19CYP2D6TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7880042-B2 antiinflammatory agents; (5 alpha ,6 alpha ,8 beta )-2-fluoro-8-methyl-5-[(2-methylquinoline-5-yl)amino]-6-(trifluoromethyl)-5,6,7,8-tetrahydronaphthalene-1,6-diol; side effect reduction BAYER SCHERING PHARMA AG (DE) 2011-02-01 US disclosed